Registry: TPLA for LUTS
Registry: TPLA for LUTS
Rationale: The treatment of lower urinary tract symptoms (LUTS) due to benign prostatic
 enlargement in men with transperineal laser ablation (TPLA) may offer advantages in
 functional outcomes and safety over current standard therapies. As the technique is
 relatively new, indications and outcomes for this treatment are subject of investigation.
 However, the technique is already applied outside clinical studies. Clinical information from
 these treatments can be useful for future research. The aim of this study is to collect data
 on patients treated with transperineal laser ablation of the prostate outside clinical trials
 and to provide data on safety and functional outcomes in these patients in order to improve
 treatment.

 Objective: To assess long-term efficacy of transperineal laser ablation for lower urinary
 tract symptoms, to assess functional outcomes, to assess safety, to determine baseline
 patient characteristics, to collect information on possible differences between centres
 applying treatment of transperineal laser ablation and to explore the optimal treatment
 indications and possible limitations.

 Study design: This is an international prospective observational study in which data is
 recorded of patients who are treated with transperineal laser ablation for lower urinary
 tract symptoms.

 Study population: Male patients treated with transperineal laser ablation for lower urinary
 tract symptoms due to benign prostatic enlargement.

 Main study parameters/endpoints: The primary endpoint of this study is long-term efficacy of
 transperineal laser ablation for lower urinary tract symptoms measured by the time until
 surgical retreatment.
Inclusion Criteria:

 -  Male

 -  Presenting with lower urinary tract symptoms

 -  Indication for transperineal laser ablation

 -  Signed informed consent form

 Exclusion Criteria:

 -  Age < 18 years

 -  Previous or active treatment for prostate cancer (active surveillance is not seen as
 active treatment)